Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

TD Cowen Downgrades NGM Biopharmaceuticals to Market Perform, Lowers Price Target to $1.55

Author: Benzinga Newsdesk | February 28, 2024 06:44am
TD Cowen analyst Ritu Baral downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Outperform to Market Perform and lowers the price target from $4 to $1.55.

Posted In: NGM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist